SCHEMBL450880

SCHEMBL450880

C1=CC2Oc3ccccc3C2C=C1

nearest known ligand 0.40

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.38
ME2 P23368 1/20 0.37
ME1 P48163 1/20 0.37
ME3 Q16798 1/20 0.37
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
ABCG2 Q9UNQ0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19294638 0.77 POLB (0.37)
SCHEMBL13752373 0.77 KDM4E (0.38) MAOA
SCHEMBL13138773 0.77 ABCG2 (0.39) CHRM1ME2ME1ME3MAOA
SCHEMBL9949003 0.75 ALDH1A1 (0.46)
SCHEMBL24050439 0.73 ALDH1A1 (0.39)
SCHEMBL12175649 0.73
SCHEMBL19336308 0.73
SCHEMBL22367908 0.73 CA12 (0.31)
SCHEMBL22421898 0.73 AHR (0.36)
SCHEMBL21546207 0.73 CA12 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113861128-A Polymerizable compound and optically anisotropic body 江苏创拓新材料有限公司 2021-12-31 CN claimed
EP-1852420-B1 Indole compounds for treating respiratory disorders ONO PHARMACEUTICAL CO (JP) 2012-10-17 EP claimed
WO-1994001428-A1 ASYMMETRIC SYNTHESIS OF HEXAHYDRODIBENZOFURANS BY STEREOSPECIFIC INVERSION OF ORTHO SUBSTITUTED 2-PHENYLCYCLOHEXANOLS RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1994-01-20 WO claimed
US-12600730-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2026-04-14 US disclosed
US-20260083735-A1 ABHD6 ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2026-03-26 US disclosed
EP-4596555-A1 ABHD6 ANTAGONIST ONO Pharmaceutical Co., Ltd. (JP) 2025-08-06 EP disclosed
US-20240270755-A1 SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2024-08-15 US disclosed
US-11981682-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2024-05-14 US disclosed
WO-2024071398-A1 ABHD6 ANTAGONIST 小野薬品工業株式会社 2024-04-04 WO disclosed
EP-4317153-A1 ABHD6 ANTAGONIST ONO Pharmaceutical Co., Ltd. (JP) 2024-02-07 EP disclosed
CN-114560828-B Polymerizable compound and optically anisotropic body formed therefrom 江苏创拓新材料有限公司 2024-01-26 CN disclosed
US-20030087831-A1 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2003-05-08 US disclosed
EP-1306373-A1 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2003-05-02 EP disclosed
EP-1262100-A1 FAN TYPE CHEMICALS DIFFUSING DEVICE Fumakilla Limited (JP) 2002-12-04 EP disclosed
EP-1236726-A1 TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-09-04 EP disclosed
EP-1234834-A1 1,3,4-OXADIAZOLIN-2-ONE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-08-28 EP disclosed
EP-1215203-A1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-19 EP disclosed
EP-0888380-A1 PROCESS FOR ALKYLATING AND SMILES REARRANGEMENT OF HYDROXY AROMATICS HOECHST MARION ROUSSEL, INC. (US) 1999-01-07 EP disclosed
WO-1997034916-A1 PROCESS FOR ALKYLATING AND SMILES REARRANGEMENT OF HYDROXY AROMATICS HOECHST MARION ROUSSEL, INC. (US) 1997-09-25 WO disclosed
US-4983587-A Aerobic fermentation of fungus DSM 4431 BASF AKTIENGESELLSCHAFT (DE) 1991-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087831-A1 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient SERPINB1, ELANE, MMP8 CHRM1 1483/4885ME2 2979/4885ME1 2610/4885
US-20240270755-A1 SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS ABHD6, ABHD16A, PITHD1 CHRM1 4841/4885ME2 3579/4885ME1 3285/4885
US-11981682-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ABHD6, ABHD16A, PITHD1 CHRM1 4844/4885ME2 3604/4885ME1 3292/4885
US-12600730-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ABHD6, ABHD16A, HDHD5 CHRM1 4070/4885ME2 3883/4885ME1 2744/4885
US-20260083735-A1 ABHD6 ANTAGONIST ABHD6, ABHD16A, ABHD12 CHRM1 3741/4885ME2 2852/4885ME1 2721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.